6ML vs BSLN: Side-by-Side Comparison
Compare MOLECULAR PARTNERS SF 1 (6ML) and Basilea Pharmaceutica AG (BSLN) side by side: market cap EUR 126.79M vs CHF 660.91M. Financials, growth and model signals on Bullrun.
| Metric | 6ML | BSLN |
|---|---|---|
| Company | MOLECULAR PARTNERS SF 1 | Basilea Pharmaceutica AG |
| Country / Exchange | Switzerland · F | Switzerland · SW |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Market cap | EUR 126.79M | CHF 660.91M |
| P/E ratio | — | 17.0 |
| Dividend yield | — | — |
| Valuation model | — | — |
| Revenue (latest FY) | — | CHF 232.38M |
| Revenue growth YoY | — | +11.4% |
| Net income | — | CHF 40.24M |
| Gross margin | — | 83.1% |
| Diluted EPS | — | — |